AgroPages-Exercise of commercial options-Agricultural news

Eden Research plc, a leading UK agrochemical development company, is pleased to announce that its licensee, Cheminova AS, has exercised its option, under an agreement dated 14 May 2007, to take a further seventeen countries as part of the rollout programme for Eden's Terpene based Botrytis treatment.

Under the terms of the agreement, Cheminova will be responsible for local field trials and relevant national registrations.

Tim Griffiths, the Chief Executive of Eden Research plc, said: "Cheminova has decided to exercise its option to extend the territories for its rights to commercialise 3AEY in most of Europe and much of the Americas and the CIS. This is a significant milestone in the rollout and development of 3AEY."

Subscribe Email:		*
Name:
Mobile Number:

A Deep exploration into Regulatory Analysis, Join upcoming <2024 CROs & CRAOs Manual>Magazine

Join 2024 Formulation & Adjuvant Technology Magazine to Show Your Insights and Innovation SolutionsMagazine

BioEx 2024 successfully held: Biological innovation leading the way towards sustainable agricultureEvent

Exercise of commercial options

More from AgroNewsChange

Magazine

Hot Topic More

NEWSLETTER